Emergent BioSolutions Q2 EPS $(1.06) Misses $(0.47) Estimate, Sales $337.90M Beat $217.03M Estimate
Portfolio Pulse from Benzinga Newsdesk
Emergent BioSolutions (NYSE:EBS) reported Q2 losses of $(1.06) per share, missing the analyst consensus estimate of $(0.47) by 125.53%. This is a 23.26% decrease over losses from the same period last year. However, the company reported quarterly sales of $337.90 million, beating the analyst consensus estimate of $217.03 million by 55.69%, a 39.23% increase over sales from the same period last year.
August 08, 2023 | 8:34 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Emergent BioSolutions reported a larger than expected loss for Q2 but beat sales estimates.
Emergent BioSolutions reported a larger than expected loss for Q2, which is likely to negatively impact the stock price. However, the company beat sales estimates, which could offset some of the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100